Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 103

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Strategies for late phase preclinical and early clinical trials of senolytics

Wissler Gerdes, Erin O., Misra, Avanish, Netto, Jair Machado Espindola, Tchkonia, Tamar, Kirkland, James L. · 2021 · Mechanisms of Ageing and Development

Abstract

Cellular senescence and the hallmarks of aging contribute to age-related disease and dysfunction. The Unitary Theory of Fundamental Aging Mechanisms highlights the interdependence among the hallmarks of aging and suggests that by intervening in one fundamental aging process, most or all of the other processes could be impacted. Accumulation of senescent cells is associated with frailty, cardiovascular disease, obesity, diabetes, cognitive decline, and other age- and/or chronic disease-related disorders, suggesting that senescent cells are a target for intervention. Early preclinical data using senolytics, agents that target senescent cells, show promising results in several aging and disease models. The first in-human trials using the senolytic combination of Dasatinib and Quercetin indicated reduced senescent cell burden in adipose tissue of diabetic kidney disease patients and improved physical function in patients with idiopathic pulmonary fibrosis. Clinical trials with other senolytics, including the flavonoid Fisetin and BCL-xL inhibitors, are underway. These results from preclinical and early clinical trials illustrate the potential of senolytics to alleviate age-related dysfunction and diseases. However, multiple clinical trials across different aging and disease models are desperately needed. Parallel trials across institutions through the Translational Geroscience Network are facilitating testing to determine whether senolytics can be translated into clinical application.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mad.2021.111591

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 15

  1. Allsopp, 1992, Telomere length predicts replicative capacity of human fibroblasts, Proc. Natl. Acad. Sci. U. S. A., 89, 10114, 10.1073/pnas.89.21.10114 · DOI · Paper page
  2. Calcinotto, 2019, Cellular senescence: aging, cancer, and injury, Physiol. Rev., 99, 1047, 10.1152/physrev.00020.2018 · DOI · Paper page
  3. Farr, 2017, Targeting cellular senescence prevents age-related bone loss in mice, Nat. Med., 23, 1072, 10.1038/nm.4385 · DOI · Paper page
  4. Gorina, 2005, Trends in causes of death among older persons in the United States, Aging Trends, 1
  5. Greider, 1998, Telomerase activity, cell proliferation, and cancer, Proc. Natl. Acad. Sci. U. S. A., 95, 90, 10.1073/pnas.95.1.90 · DOI · Paper page
  6. Hayflick, 1961, The serial cultivation of human diploid cell strains, Exp. Cell Res., 25, 585, 10.1016/0014-4827(61)90192-6 · DOI · Paper page
  7. He, 2020, Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity, Nat. Commun., 11, 1996, 10.1038/s41467-020-15838-0 · DOI · Paper page
  8. Iske, 2020, Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation, Nat. Commun., 11, 4289, 10.1038/s41467-020-18039-x · DOI · Paper page
  9. Kirkland, 2017, Cellular senescence: a translational perspective, EBioMedicine, 21, 21, 10.1016/j.ebiom.2017.04.013 · DOI · Paper page
  10. Lidzbarsky, 2018, Genomic instabilities, cellular senescence, and aging: in vitro, in vivo and aging-like human syndromes, Front. Med. (Lausanne), 5, 104, 10.3389/fmed.2018.00104 · DOI
  11. Maher, 2021, Preventing and treating neurological disorders with the flavonol fisetin, Brain Plast., 6, 155, 10.3233/BPL-200104 · DOI
  12. Palmer, 2021, Senolytics: potential for alleviating diabetes and its complications, Endocrinology, 162, 10.1210/endocr/bqab058 · DOI
  13. Stockl, 2006, Sustained inhibition of oxidative phosphorylation impairs cell proliferation and induces premature senescence in human fibroblasts, Exp. Gerontol., 41, 674, 10.1016/j.exger.2006.04.009 · DOI · Paper page
  14. Subramanian, 2007, GSEA-P: a desktop application for gene set enrichment analysis, Bioinformatics, 23, 3251, 10.1093/bioinformatics/btm369 · DOI · Paper page
  15. Wang, 1995, Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved, Cancer Res., 55, 2284

Cited by

See all 103

Metadata

Authors
Wissler Gerdes, E. O., Misra, A., Netto, J. M. E., Tchkonia, T., & Kirkland, J. L.
Venue
Mechanisms of Ageing and Development
Publisher
Elsevier BV
Published
2021-12
Volume
200
Pages
111591
ISSN
0047-6374
Cited by
103
References
40
Language
en
Licence
Funders
  • National Institutes of Health (P01 AG62413, R01 AG072301, R01 AG61414, R33 AG61456, R37 AG13925, UH3 AG56933)
  • Noaber Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Strategies for late phase preclinical and early clinical trials of senolytics. https://app.cochat.ai/papers/10.1016/j.mad.2021.111591
The paper
Wissler Gerdes, E. O., Misra, A., Netto, J. M. E., Tchkonia, T., & Kirkland, J. L. (2021). Strategies for late phase preclinical and early clinical trials of senolytics. Mechanisms of Ageing and Development. https://doi.org/10.1016/j.mad.2021.111591

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.